TrialAnnals of oncology : official journal of the European Society for Medical Oncology2022

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

C E Geyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.